BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for <i>BRCA</i> Carriers.

Sun, Jie; Chu, Futao; Pan, Jiani; Zhang, Yaxin; Yao, Lu; Chen, Jiuan; Hu, Li; Zhang, Juan et al. · J Clin Oncol · 2023

retrospective_cohort · Level III

Where this comes from

Abstract

The absolute cumulative risk of contralateral breast cancer (CBC) for patients with <i>BRCA1</i>/<i>2</i> variants is unknown. The purpose of this study was to develop a CBC risk prediction model for assessing CBC risk for <i>BRCA1</i>/<i>2</i> carriers. The primary cohort of 491 patients with <i>BRCA1</i>/<i>2</i> variants was derived from a large series of unselected patients with breast cancer. A nomogram was established on the basis of the results of a multivariate Cox regression analysis from this cohort. This model, named BRCA-CRisk, was further validated by an independent cohort of 205 patients with <i>BRCA1</i>/<i>2</i> variants. Discrimination and calibration of the model were assessed. In the primary cohort of 491 patients, 66 developed contralateral breast cancer after a median follow-up of 7.0 years. Four variables were significantly associated with risk of CBC and were incorporated in the establishment of the BRCA-CRisk prediction model: younger age at first breast cancer (with continuous variable, <i>P</i> = .002), positive first-degree family history of breast and/or ovarian cancer (hazard ratio [HR], 1.89; 95% CI, 1.16 to 3.08; <i>P</i> = .011), variant located near the 3' region of <i>BRCA</i> (HR, 2.01; 95% CI, 1.23 to 3.30; <i>P</i> = .006), and endocrine therapy (HR, 0.54; 95% CI, 0.33 to 0.88; <i>P</i> = .013). The area under the time-dependent curves for the 5- and 10-year cumulative risks of CBC were 0.775 and 0.702, respectively. The model was well validated in the independent cohort of 205 <i>BRCA1</i>/<i>2</i> carriers, with area under the curves of 0.750 and 0.691 for 5 and 10 years, respectively. BRCA-CRisk model provides a useful tool for assessing the absolute cumulative risk of CBC for <i>BRCA1</i>/<i>2</i> carriers and may help carriers and clinicians optimally select risk-reducing strategies on the basis of individual CBC risk.

Medical subject headings